Kornimate/medical-research-clean huggingface dataset:
neural and psychiatric consequences of cannabis use in adolescents

Conditions: Cannabis Use; Depression

Summary: the goal of this study is to investigate the effects of cannabis on brain function among adolescents with depression.


Eligibility criteria:
inclusion criteria: cannabis users 1) the study team will require majority of adolescents with cannabis use to have a significant cannabis use (self-reported use on ≥15 of the prior 30 days and positive tetrahydrocannabinol (thc) urine toxicology). depression positive 1) participants with subthreshold depression, defined as a raw severity score of ≥30 on the children's depression rating scale-revised (cdrs-r, for ages 14-17) and as a raw severity score of ≥12 on the montgomery asberg depression rating scale (madrs, for ages 18-20) exclusion criteria: 1. mri contraindications such as claustrophobia, metallic ink tattoos, orthodontic braces, or pacemakers 2. positive pregnancy tests 3. neurological illnesses and medical conditions such as unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis) 4. estimated full-scale intelligence quotient (iq) ≤80 to ensure that participants have the ability to understand the study112 5. current substance use disorder (sud) other than cannabis or nicotine. 6. certified for or self-reported medical cannabis use, or intent to become certified 7. current stimulant use (methamphetamine or cocaine) by self-report or urine toxicology 8. oral contraceptives will be allowed and controlled for in order to maximize recruitment of older adolescents. depressed thc non-users: 1. psychotropic medication-free for \>1 month (or \>3 months for medications with a long half- life such as fluoxetine) prior to study enrollment. 2. diagnostic and statistical manual 5 (dsm-5) diagnoses of bipolar disorder, psychotic disorders, autism spectrum all non-cannabis substance-related disorders will be exclusionary. 3. self-injurious acts (e.g. cutting) and suicidal ideations (si) without a specific as passive si) are common in adolescent depression and will be allowed. constitutes an imminent risk to self or others (defined as active si), the withdrawn from the study and emergency procedures will be initiated immediately,

Keywords: adolescents neuroimaging functional magnetic resonance imaging (fmri) reward reward flanker task reward predication error task pain
auranofin in decreasing pain in patients with paclitaxel-induced pain syndrome

Conditions: Pain

Summary: this randomized pilot clinical trial studies whether auranofin will relieve pain following paclitaxel in patients who have previously experienced paclitaxel-induced pain. auranofin is a drug given by mouth to treat other diseases such as rheumatoid arthritis, and is being studied to see if it will decrease pain following paclitaxel.

primary objectives: i. determine whether one dose of auranofin given the day following administration of paclitaxel decreases pain as assessed by daily completion of the modified brief pain inventory scale for seven days. secondary objectives: i. assess whether auranofin is well tolerated in this setting. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients receive auranofin orally (po) on day 2. arm ii: patients receive placebo po on day 2. after completion of study treatment, patients are followed up at 21-28 days.

Eligibility criteria:
inclusion criteria: * absolute neutrophil count (anc) \>= 1500/mm\^3 * platelet count (plt) \>= 100,000/mm\^3 * creatinine =\< 2 x upper limit of normal (uln) * either serum glutamate pyruvate transaminase (sgpt) (alanine aminotransferase \[alt\]) or serum glutamic oxaloacetic transaminase (sgot) (aspartate aminotransferase \[ast\]) =\< 1.5 x uln * total/direct bilirubin =\< 1.5 x uln * alkaline phosphatase =\< 1.5 x uln * hemoglobin \>= 9 mg/dl * negative urine or serum pregnancy test performed =\< 7 days prior to registration, for women of childbearing potential only * previously experienced paclitaxel induced pain during a current or past paclitaxel treatment that the treating healthcare provider thinks is consistent with the paclitaxel-induced acute pain syndrome; note: formal documentation of prior pain is not required * scheduled to receive paclitaxel at a dose \>= 70 mg/m\^2 =\< 14 days from randomization * ability to complete the questionnaires or to do so with assistance exclusion criteria: * pregnant women * nursing women * any woman of childbearing potential or male partner of a woman of childbearing potential unwilling to employ acceptable contraception throughout the study and for at least 30 days after the last dose of the study drug * history of gold-induced disorders, including but not limited to, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or other severe hematologic disorders; history of severe allergic or anaphylactic reactions or hypersensitivity to auranofin or other gold compounds * currently receiving dilantin (phenytoin) or auranofin or another gold-containing compound * anticipated use of filgrastim (g-csf) or sargramostim (gm-csf) within 30 days after receiving auranofin * currently receiving immune-modulating therapies
health advocate for liver transplantation: improving transition of care for adolescent liver transplant recipients

Conditions: Liver Transplant; Complications; Pediatric ALL

Summary: the health advocate for liver transplant (heal-tx) transition of care pilot is a nonrandomized, open-label intervention pilot of a health advocate intervention aimed to assess feasibility and acceptability of integrating a health advocate onto the transplant team to help adolescents transition their care to adult transplant teams. across studies, health advocate roles vary, and can include coordinating medical care treatment, facilitating financial assistance (e.g., taxi vouchers), and connecting patients to community resources, which can improve self-management, mitigate social risks, and lead to better communication between the healthcare system and the family. in this pilot, the investigators will adapt this intervention for adolescent/young adult liver transplant patients and measure acceptability and feasibility according to re-aim.


Eligibility criteria:
inclusion criteria: 1. patient has received a liver transplant \>1 year ago 2. study team has screened patient and discussed with the primary transplant practitioner that patient may benefit from the health advocate program. 3. patient has an unmet social risk (e.g., food insecurity) or mlvi \>/= 2.0. 4. patient will be transferred to adult transplant team in \<6 months. 5. patient can read and write english or spanish 6. patient is between 18-25 years old and can provide informed consent. 7. patient has a working phone and smart device capable of video and/or audio virtual visits via zoom. exclusion criteria: * patient has significant cognitive impairment. * does not meet age criteria * patient is a ward of the state. * non-english, non-spanish speakers. * non-us residents.

Keywords: health advocate patient navigator
umcc 9609 tretinoin in preventing cancer of the cervix in patients with cervical neoplasia

Conditions: Cervical Cancer; Precancerous/Nonmalignant Condition

Summary: rationale: tretinoin may help cervical neoplasia cells develop into normal cervical cells. it is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia. purpose: randomized clinical trial to study the effectiveness of tretinoin in preventing cervical neoplasia from developing into cervical cancer.

objectives: i. determine whether topical tretinoin reduces the number of viral genome copies of human papilloma virus (hpv) per cell and inhibits hpv e6/e7 gene expression in patients with cervical dysplasia. ii. determine the dose of tretinoin for use in a definitive trial that produces the best overall modulation of these biomarkers. outline: this is a randomized, multicenter study. patients are stratified according to cervical intraepithelial neoplasia classification (ii vs iii). patients are randomized to 1 of 4 arms. arm i: patients receive low-dose tretinoin topically via cervical cap and polyurethane ether foam sponge changed daily for 4 days. arm ii: patients receive intermediate-dose tretinoin as in arm i. arm iii: patients receive high-dose tretinoin as in arm i. arm iv: patients receive placebo topically as in arm i therapy. patients are followed for 6 months. projected accrual: a total of 180 patients (45 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven cervical dysplasia (cervical intraepithelial neoplasia ii or iii) lesions must be delineated after colposcopic biopsy no pap smears suspicious for invasive carcinoma no positive endocervical curettage patient characteristics: age: over 14 performance status: karnofsky 80-100% life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified immunologic: no proliferative skin disorder (e.g., psoriasis) no diagnosed autoimmune disorders no allergy to tretinoin or latex other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception (except intrauterine device) during and for 3 months after study normal diet with adequate protein and carbohydrate intake no in-utero exposure to diethylstilbesterol no prior malignancy no prior toxic shock syndrome prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 1 week since prior tretinoin no prior retinoids (greater than 25,000 iu vitamin a or equivalent for at least 3 months) no other tretinoin during or for 3 months after study endocrine therapy: no concurrent regular steroids radiotherapy: not specified surgery: see disease characteristics other: no concurrent regular anticoagulant medication no concurrent nutritional supplements other than 2 multivitamins per day

Keywords: cervical cancer cervical intraepithelial neoplasia grade 2 cervical intraepithelial neoplasia grade 3
folate one-carbon malnutrition as the metabostemness risk factor of malignancy tumor development of nsclc patients

Conditions: Lung Cancer, Nonsmall Cell

Summary: non-small cell lung cancer (nsclc) accounts for more than two-thirds of lung cancer, which is the leading cause of cancer deaths in taiwan. the overall prognosis of nsclc is poor with low 5-year survival rates. recent advances suggest that malignancy nsclc cancers are the cancer stem cell (csc) diseases. the stemness potentials of csc with epithelial-mesenchymal transdifferentiation ensure their invasion and disseminate to metastsis organs. the self-renewal property of csc mediates intrinsic drug resistance to cytotoxicity therapy and promoted aggressive relapse tumour. metabolic reprogramming on bioenergetics of malignant cancer cells has been proposed as the key mediator in the stemness csc development. malignancy cells uptake glucose for fermented glycolysis to produce lactate which release resulted in acidified microenvironment to trigger the mtor and sonic hedgehog metabolic stress signaling in supporting csc stemness potentials. the metabostemness of cancer cells is the new-dimensional hallmark of malignancy tumour, which may serve as the diagnostic markers for the early detection of malignancy cancers. folate-mediated one carbon metabolism coordinates glucose into amino acid metabolism to tailor the fuel metabolites in supporting macromolecule synthesis and to sustain the bioenergetics requirement. acting as the metabolic stressor, low folate intake is associated with increased risks of lung cancers. folate and one-carbon nutrient status of nsclc patients in taiwan, however, has not been assessed. the role of low folate metabolic stress (lfms) in metabostemness marker and metastasis potentials of malignancy nsclc is unexplored. the causal effect and the working mechanisms by which lfms promoted nsclc malignancy remain elusive.


Eligibility criteria:
inclusion criteria: * surgeon diagnosed as the first time having non-small cell lung cancer from the surgical clinic of national taiwan university hospital exclusion criteria: * patients suffer from major diseases such as heart, liver, kidney, or peripheral arterial disease, or having mental illness * diabetes and non-lung cancer patients * pregnancy, breast-feeding pregnant women

Keywords: one-carbon metabolism folate choline metabolomic marker cancer risk
study of yili "changqing" pro-abb yoghurt in the improvement of human gastrointestinal tract system

Conditions: Constipation; Dyspepsia; Flatulence; Abdominal Pain

Summary: the purpose of this study is to determine whether yili "chang qing" pro-abb yoghurt is effective in improving mild constipation and the intestinal micro-ecology environment \& alimentation.


Eligibility criteria:
inclusion criteria: 1. male or female subjects, 25-45 yrs; 2. non-specific and/or moderate constipation; 3. irregular or occasional gastrointestinal disorders (flatulence, gurgling, feeling heavy after eating, abdominal pain); 4. slow transit or irregular bowels movements (abnormal feces solidity, bowel movements decreased, e.g. every 2-3 days or less than 3 times per week). exclusion criteria: 1. diagnosed as chronic constipation; 2. treated gastrointestinal symptoms; 3. lactose intolerance; 4. treatment by analgesic such as aspirin and paracetamol; 5. had laxatives or other remedies to promote digestion 2 weeks prior to the study start; 6. consuming dairy products or supplements containing pro/pre-biotic 10 days prior to the study start; 7. currently suffering from diarrhea.
ono-4538 phase i study in patients with solid tumor

Conditions: Advanced Solid Tumors; Recurrent Solid Tumors

Summary: the objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ono-4538 administered to korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.


Eligibility criteria:
inclusion criteria: * the treatment phase has been completed in the ono-4538-13 study exclusion criteria: * the development of pd is identified by the principal or sub investigator according to the recist guideline (version 1.1) only in case in which the unplanned tumor assessment with diagnostic image is performed in the treatment phase of ono-4538-13 study. * it is determined that continuing the treatment is not appropriate because the worsening of clinical symptoms attributed to disease progression occurs.
thoracolumbar burst fracture treated with pedicle screws: radiographic outcomes

Conditions: Burst Fracture

Summary: the surgical results of thoracolumbar and lumbar burst fracture have been reported to be comparable between patients with and without fusion in a midterm follow-up. there is, however, no report comparing the results of fusion and non-fusion with a long-term follow-up. therefore, a long term comparative study is still needed to focus on the issues of functional and radiographic outcomes, especially preservation of the motion segment in the long run, to determine whether fusion should be a routine procedure for surgically treated burst fractures of the thoracolumbar and lumbar spines. therefore, we report herein a long-term comparative study of fusion and non-fusion based on our previous work, with an average 134 months of follow-up.


Eligibility criteria:
inclusion criteria: * neurologically intact spine with a kyphotic angle more than 20o, decreased vertebral body height more than 50% or a canal compromise more than 50%; * incomplete neurological deficit with a canal compromise less than 50%; * complete neurological deficit; * multilevel spinal injury or multiple trauma. exclusion criteria: * progression of the neurological deficit; * a canal compromise still more than 50% in those who showed no improvement of the neurological deficit.

Keywords: burst fracture, kyphotic angle, surgical outcome
feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotide

Conditions: Irritable Bowel Syndrome (IBS)

Summary: this study is designed to provide information on feasibility and reproducibility of barostat assessments of colorectal sensory functions and compliance and their pharmacological modulation


Eligibility criteria:
inclusion criteria: * a positive diagnosis of ibs. * subjects must either have been surgically sterilized, hysterectomized at least 6 months prior to screening, be postmenopausal or be using a double-barrier local * contraception. * able to communicate well with the investigator, to understand and comply with the requirements of the study. understand and sign the written informed consent exclusion criteria: * history of or evidence for structural diseases/conditions that affect the gastrointestinal system. * other diseases or conditions that in the opinion of the investigator significantly affect colorectal sensitivity. * evidence of occult blood at stool analysis, or history of rectal bleeding. * using or planning to use drugs or agents during the study period that alter gi physiology and visceral perception.

Keywords: barostat distention ibs irritable bowel syndrome colorectal sensation modulation reproducibility
the application of negative atrioventricular hysteresis in cardiac resynchronization therapy with multipoint pacing

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate the application of negative av hysteresis (navh) to improve electrical synchrony in multipoint pacing (mpp) cardiac resynchronization therapy (crt) patients.


Eligibility criteria:
inclusion criteria: * scheduled for implantation of an mpp-enabled sjm quadripolar crt pacing system * qrs duration \> 140 ms * left bundle branch block documented * ability to provide informed consent for study participation * willing to comply with the study evaluation requirements * at least 18 years of age exclusion criteria: * resting ventricular rate \>100 bpm * intrinsic pr interval \> 300 ms * paroxysmal or persistent atrial tachycardia or atrial fibrillation documented * a recent myocardial infarction, ablation, drug intoxication, electrolyte imbalance, or any condition within the last 90 days that would be contraindicated for crt programming changes in the opinion of the investigator * women who are pregnant or who plan to become pregnant during the study

Keywords: negative atrioventricular hysteresis cardiac resynchronization multipoint
evaluation of muscle sto2 as a prognostic factor after out of hospital cardiac arrest

Conditions: Cardiac Arrest

Summary: out of hospital cardiac arrest is a major health problem. prognosis is still poor even after return to spontaneous circulation. the pathophysiology of cardiac arrest implies ischemia-reperfusion and sepsis like syndrome. these phenomenons can lead to microvascular dysfunction explaining probably multi-organ failure after cardiac arrest. few means allow the exploration of microvascular function in human. muscle sto2 is a technique allowing the assessment of microvascular function non-invasively. the aim of this study is to evaluate muscle sto2 as a prognostic factor after out of hospital cardiac arrest.

out of hospital cardiac arrest is a major health problem accounting for 375000 deaths each year in europe. even after return to spontaneous circulation, survival is poor because of complications such as post-anoxic encephalopathy and multi-organ failure. the pathophysiology of cardiac arrest implies ischemia-reperfusion and sepsis like syndrome. these conditions are frequently associated with microvascular dysfunction that can be the "motor" of multi-organ failure. few means allow the exploration of microvascular function in human. recently, sto2, a non-invasive technique assessing microvascular function has been described. this technique measures the tissular saturation of a muscle using the near-infrared spectroscopy technique. it has been described to be a good prognostic factor during haemorrhagic shock state. dynamic parameters such as reperfusion slope allow discriminating between survivors and survivors after severe sepsis. this dynamic test assesses the microvasculature recruitment that could be a marker of better prognosis. the aim of this study is to evaluate muscle sto2 as a prognostic factor after out of hospital cardiac arrest.

Eligibility criteria:
inclusion criteria: * out of hospital cardiac arrest * patient aged between 18 and 80 years * having a social security system exclusion criteria: * pregnant women, lack of appropriate consent
use of domperidone for treatment of upper gastrointestinal disorders

Conditions: Gastroparesis

Summary: this is an expanded access to investigational drug program available through the fda. some specific conditions to qualify for this program includes gastroesophageal reflux disease with upper gi symptoms, gastroparesis, and chronic constipation. patients failing standard therapies for these conditions may be eligible to receive domperidone. this program facilitates availability of investigational drugs, (such as domperidone) to patients with serious diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor or treat the patients's disease or condition. authorization must be obtained from fda prior to the importation, interstate shipment and administration of domperidone.


Eligibility criteria:
inclusion criteria: 1. male or female 2. age 18 and older 3. symptoms or manifestations secondary to motility disorders of the upper gi tract. these include gastroparesis, functional dyspepsia, gastroesophageal reflux disease that are refractory to standard therapy. 4. patients must have a comprehensive evaluation to eliminate other causes of their symptoms. this includes a history and physical examination. a recent (within 3 years) evaluation of the upper gi tract with either upper endoscopy or upper gi radiographic series. baseline blood tests suggested are electrolytes, magnesium, and prolactin level. 5. patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including: * increased prolactin levels * breast changes * extrapyramidal side effects * cardiac arrhythmias including qt prolongation (increased risk with the drugs listed in the appendix) exclusion criteria: history of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and torsade des pointes. patients with minor forms of ectopy (pacs) are not necessarily excluded. 2. clinically significant bradycardia, sinus node dysfunction, or heart block. prolonged qtc (qtc \> 450 milliseconds for males, qtc \> 470 milliseconds for females). 3. clinically significant electrolyte disorders. these include significant hypokalemia, hyperkalemia, hypomagnesemia, and hypermagnesemia that cannot be corrected with treatment of these electrolyte abnormalities. 4. gastrointestinal hemorrhage or obstruction. 5. presence of a prolactinoma (prolactin-releasing pituitary tumor). 6. pregnant or breast feedings female. 7. known allergy to domperidone.

Keywords: gastroparesis
evaluating the dietary supplement anatabloc in thyroid health-asap (antabloc supplementation autoimmune prevention)

Conditions: Thyroiditis, Autoimmune

Summary: this is a study to evaluate the safety, tolerability, and potential effects of anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.

this is a 5-visit, 12-week, double-blind, randomized, placebo-controlled, parallel-group study.

Eligibility criteria:
inclusion criteria: * adults 18-70 years of age * having positive antibodies against thyroid peroxidase * having sonographic evidence consistent with a diagnosis of hashimoto's thyroiditis exclusion criteria: * having evidence of end-stage thyroiditis * being a current smoker or smokeless tobacco user * be taking systemic glucocorticoids, interferon-alpha, anti-cd20 antibody, or anti-ctla-4 antibody * be taking any medication for treatment of autoimmune thyroiditis other than l-thyroxine or equivalent

Keywords: hashimoto disease thyroiditis